Evidence map›Paper›PMID 27512704›Full record

ReviewJournal of research in pharmacy practice

Pharmaceutical laws and regulations in Iran: An overview.

Pardis Zaboli, Amir Hashemi-Meshkini, Mehdi Varmaghani, Hadi Gholami, Iman Vazirian, Hedieh-Sadat Zekri, Shahriar Eslamitabar, Abbas Kebriaeezadeh

Abstract readReview
In one paragraph

Review in Journal of research in pharmacy practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Policies to improve access to pharmaceutical products in shortage: the experience of Iran food and drug administration.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2019
    Article
  13. Article
  14. Article
  15. Trends in Iran Pharmaceutical Market.Iranian journal of pharmaceutical research : IJPR · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pardis ZaboliPharmaceutical Management and Economics Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Amir Hashemi-MeshkiniDepartment of Pharmacoeconomics and Pharmaceutical Administration, Tehran University of Medical Sciences, Tehran, Iran.
Mehdi VarmaghaniDepartment of Pharmacoeconomics and Pharmaceutical Administration, Tehran University of Medical Sciences, Tehran, Iran.
Hadi GholamiDepartment of Pharmaceutics, Tehran University of Medical Sciences, Tehran, Iran.
Iman VazirianDepartment of Pharmaceutics, Tehran University of Medical Sciences, Tehran, Iran.
Hedieh-Sadat ZekriDepartment of Economics, Shahid Beheshti University, Tehran, Iran.
Shahriar EslamitabarDepartment of Pharmaceutics, Tehran University of Medical Sciences, Tehran, Iran.
Abbas KebriaeezadehPharmaceutical Management and Economics Research Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Pharmacoeconomics and Pharmaceutical Administration, Tehran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pharmaceutical legal framework is a very important infrastructure in achieving predefined goals in pharmaceutical sector: Accessibility, quality, and rational use of medicine. This study aims to review the current pharmaceutical sector-related legal provisions in Iran where the Food and Drug Organization (FDO) is in charge of regulating all issues related to the pharmaceutical sector. The main laws and regulations enacted by parliament and cabinet and even internal regulations enacted by the Ministry of Health or Iran FDO are reviewed. Different laws and regulations are categorized according to the main goals of Iran national drug policy.

Indexed as

Accessibilityavailabilitycounterfeit medicinespharmaceutical trade-related aspectsrational use of medicine

Identifiers

PMID27512704
PMCPMC4966232

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.